The Interministerial Commission on Drug Prices (CIMP) has proposed, in its last meeting, the financing of the first biosimilar medicine of the active ingredient eculizumab, in adults and children for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). This is stated in the information note issued by the organization after its May session.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
